clement, Author at BaseLaunch

Alentis raises 12.5 million Swiss francs

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…

clement03.03.2020

All Portfolio news

T3 Pharma raises over $12 million

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…

clement02.03.2020

All Portfolio news

Versameb raises 6.4 million Swiss francs

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…

clement01.03.2020

Features

CHF 15M in Series A Financing, raised by ImmunOs

ImmunOs Therapeutics AG is a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer. They have recently…

clement17.12.2019

Features

KPMG: Reshaping the future of pharma

From our partner, KPGM: The rules of engagement in the global pharmaceutical industry are changing rapidly with disruption in this industry already well underway. Two…

clement06.12.2019

Company interviews Interviews

“The first steps are slow and then suddenly things start rolling”

After more than 25 years in the pharma business, Andreas Katopodis founded the biotech company Anaveon together with Professor Onur Boyman. In 2019, the startup…

clement06.12.2019

Features

15 companies chosen for Phase 1

The selection committee has chosen 15 promising projects for Phase I. The projects all focus on developing innovative technologies to dramatically change patient outcomes in a variety…

clement03.10.2019

Features

In the news: From start-ups to the six Swiss exchange – A Swiss success story

Switzerland is consistently ranked the most innovative country in the world, especially when it comes to life sciences. Abi Millar, from Pharma Technology Focus, looks…

clement03.10.2019

Features

Looking for biopharma professionals with experience in areas such as R&D/commercial/BD&L to support emerging biotech companies

Starting a biotech and developing drugs needs world class science as a foundation. But equally important is to back up the (usually) academic inventors of…

clement23.09.2019

Interviews

Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine

“We make no compromises in creating the highest potential company” Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond…

clement30.07.2019

clement

Alentis raises 12.5 million Swiss francs

T3 Pharma raises over $12 million

Versameb raises 6.4 million Swiss francs

CHF 15M in Series A Financing, raised by ImmunOs

KPMG: Reshaping the future of pharma

“The first steps are slow and then suddenly things start rolling”

15 companies chosen for Phase 1

In the news: From start-ups to the six Swiss exchange – A Swiss success story

Looking for biopharma professionals with experience in areas such as R&D/commercial/BD&L to support emerging biotech companies

Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us